The Alopecia Areata Severity Scale

Alopecia areata (AA) is a widespread autoimmune disease characterized by hair loss on the scalp, face, and body, affecting around 2% of the global population. Since 1902, classification of AA has been broad and does not fully account for the range of severity levels or psychosocial impacts of the condition. Over time, assessments of AA severity have focused solely on the extent of scalp hair loss, with other factors evaluated independently. Since AA is a complex autoimmune disease influenced by multiple factors beyond scalp hair loss, it is important to consider these additional factors to improve patient care and enhance collaboration among healthcare providers.

Fine-Tuning AA Assessment
To address these limitations, a new AA severity scale was developed by a panel of 22 dermatology experts specializing in AA, including a core team of 6 experts who led the survey development and analysis, with insights from both clinical practice and existing literature on AA severity. This collaborative process concluded with a final consensus vote to formalize the scale. The newly established AA Scale categorizes AA into 3 levels of severity based on scalp hair loss: mild cases, involving up to 20% scalp hair loss; moderate cases, with 21% to 49% scalp hair loss; and severe cases, in which hair loss ranges from 50% to 100% of the scalp (Table 1). This structured approach supports a more precise assessment of AA severity, improving treatment planning and patient care.

Table 1. Alopecia Areata Scale.

In addition, the scale includes secondary criteria that may elevate a patient’s severity classification. These criteria include psychosocial distress, visible loss of eyebrows or eyelashes, a lack of response to 6 months of treatment, and signs of rapid hair loss. This framework enables a more in-depth approach to AA severity, addressing both clinical and psychosocial dimensions. Loss of eyebrows and eyelashes, treatment resistance, and rapid progression are especially prioritized as key indicators for severity upgrades. Additionally, the psychosocial criteria, often evaluated through patient self-reports, acknowledge the impact of AA on emotional well-being, emphasizing the condition’s effects on quality of life.

The AA Scale is designed to offer health care providers a standardized tool that facilitates consistent and reliable assessments of AA severity across clinical practices. By including practical metrics such as scalp hair loss extent, involvement of specific sites, psychosocial impact, and treatment response, this scale aims to enhance the consistency and reliability of AA severity classification in both clinical and research environments. This scale represents a significant advancement in AA management, offering clinicians a framework to support tailored treatment strategies and ultimately improve patient care outcomes.

Reference:
King BA, Mesinkovska NA, Craiglow B, et al. Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort. J Am Acad Dermatol. 2022;86(2):359-364. doi:10.1016/j.jaad.2021.08.043